Cargando…
An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States
INTRODUCTION: The treatment with tyrosine kinase inhibitors (TKIs) has drastically improved the outcome of chronic myeloid leukemia (CML) patients. This study was conducted to examine the risk of secondary cancers (SCs) in the CML patients who were diagnosed and treated in the TKI era in the United...
Autores principales: | Kumar, Vivek, Garg, Mohit, Chaudhary, Neha, Chandra, Abhinav Binod |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813591/ https://www.ncbi.nlm.nih.gov/pubmed/29456888 http://dx.doi.org/10.7717/peerj.4342 |
Ejemplares similares
-
Racial disparities in incidence & survival of Kaposi's sarcoma in the United States
por: Kumar, Vivek, et al.
Publicado: (2019) -
The TKI Era in Chronic Leukemias
por: De Novellis, Danilo, et al.
Publicado: (2021) -
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017) -
Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017) -
Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)